Michael O'Riordan is a Senior Journalist for TCTMD, specializing in the field of cardiology and cardiovascular research. With a focus on providing up-to-date and accurate information, Michael's articles cover a wide range of topics including clinical trials, treatment options, and emerging trends in the field of cardiology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Michael O'Riordan's articles predominantly cite data and cover topics related to cardiovascular disease, medical research, treatment options, and risk factors. He would likely be receptive to pitches offering insights from experts in the healthcare and pharmaceutical industry who can provide informed perspectives on new research findings, treatment developments, or changes in medical guidelines related to cardiovascular diseases.
Given his focus on citing data extensively in his coverage, he may appreciate pitches that offer access to proprietary or exclusive datasets relevant to the topics he covers. Additionally, sources with a deep understanding of scientific methodologies and clinical trial design could capture Michael's interest.
While there is no specified geographic focus for Michael's work, his articles appear internationally focused based on the subjects covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Michael O Riordan
No impact was seen on mortality between the invasive and medical arms, but other endpoints may mean more to patients.
By: Michael O Riordan
The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.
The majority of FDA-recalled devices made it to market via the 510(k) pathway, which doesn't require new clinical or safety data.
By: Michael O Riordan
In dueling perspectives, experts make their case for and against going with PCI before even trying antianginal medications.
The study reinforces the need to take the environment into account when focusing on CVD risk prevention, say experts.
Stepwise, perioperative cardiac screening can help clinicians decide when to proceed with surgery or pause for more testing.
With patients surviving longer, there is a need to address long-term risks of CVD associated with cancer, say experts.
In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.
Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.
By: Michael O Riordan
Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.
(833) 317-6278 
